PDCD1 and melanoma: In the last decade, immunotherapeutic strategies that inhibit CTLA-4 and PD-1/PD-L1, the well-known immunological checkpoints, have shown remarkable success in the treatment of cancer, especially melanoma and Hodgkin’s lymphoma [10].